Study on ERCC1, XPD and XPA polymorphisms for prediction of platinum-based chemotherapy sensitivity in non-small lung cancer

Chinese Journal of Cancer Prevention and Treatment

Volumn 15, Issue 17, 2008, Pages 1285-1288

  Liu, Yan Fei ^a   Guan, Xiao Xiang ^a   Chen, Long Bang ^a   Chen, Yi Tian ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Carcinoma; Genotype; Lung neoplasms genetics; Non small cell lung; Polymerase chain reaction

Indexed keywords

ASPARAGINE; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLYCINE; LYSINE; PACLITAXEL; PLATINUM COMPLEX; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; INDIVIDUALIZATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PATIENT CARE; POLYMERASE CHAIN REACTION; PREDICTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT OUTCOME;

EID: 68949219423     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Parkin D M, Bray F, Ferlay J, et al. Estimating the world cancer burden: globocan 2000 [J]. Int J Cancer, 2001, 94(2): 153-156.
2. Guilbert J J. The world health report 2002-reducing risks, promoting healthy life [J]. Educ Health (Abingdon) 2003, 16(2): 230.
3. Rosell R, Lord R V, Taron M, et al. DNA repair and cisplatin resistance in non-small-cell lung cancer [J]. Lung Cancer, 2002, 38(3): 217-227.
4. Chinese source.
5. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer [J]. Lung Cancer, 2007, 56(2): 281-288.
6. Yin J, Vogel U, Ma Y, et al. A haplotype encompassing the variant allele of DNA repair gene polymorphism ERCC2/XPD Lys751G1n but not the variant allele of Asp312Asn is associated with risk of lung cancer in a northeastern Chinese population [J]. Cancer Genetics Cytogenetics, 2007,175(1): 47-51.
7. Chinese source.
8. Park J Y, Park S H, Choi J E, et al. Polymorphisms of the DNA repair gene xeroderma pigmentosum group A and risk of primary lung cancer [J]. Cancer Epidemiol Biomarkers Prev, 2002,11(10 Pt 1): 993-997.
9. Lunn R M, Helzlsouer K J, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency [J]. Carcinogenesis, 2000,21(4): 551-555.
10. Park D J, Zhang W, Stoehlmacher J, et al. ERCC1 genetic polymorphisms as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy [J]. Clin Adv Hematol Oncol, 2003, 1(3): 162-166.
11. Chinese source.
12. Drapkin R, Sancar A, Reinberg D. Where transcription meet repair [J]. Cell, 1994,77(1): 9-12.
13. Dybdahl M, Vogel U, Frentz G, et al. Polymorphisms in the DNA repair gene XPD: correlation with risk and age at onset of basal cell carcinoma [J]. Cancer Epidemiol Biomark Prev, 1999,8(1): 77-81.
14. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis [J]. Int J Med Sci,2007,4(2): 59-71.
15. De-Ruyck K, Szaumkessel M, De-Rudder I, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk [J]. Mutat Res,2007,631(2): 101-110.
16. Park D J, Stoehlmacher J, Zhang W, et al. A Xeroderma Pigmentosum Group D Gene Polymorphism Predicts Clinical Outcome to Platinum-based Chemotherapy in Patients with Advanced Colorectal Cancer[J]. Cancer Res, 2001,61(24): 8654-8658.
17. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/ Cisplatin-Treated Advanced Non-Small Cell Lung Cancer patients [J]. Clin Cancer Res,2008,14(6): 1797-1803.
18. Chinese source.